Brain aging in Type II GM1 gangliosidosis.
BACKGROUND: GM1 gangliosidosis is an inherited, progressive, and fatal neurodegenerative lysosomal storage disorder with no approved treatment. Correlations with clinical outcome assessments indicate evaluations of predicted brain aging may be an important candidate neuroimaging outcome measure for clinical trials in GM1 gangliosidosis.
BACKGROUND: GM1 gangliosidosis is an inherited, progressive, and fatal neurodegenerative lysosomal storage disorder with no approved treatment. Correlations with clinical outcome assessments indicate evaluations of predicted brain aging may be an important candidate neuroimaging outcome measure for clinical trials in GM1 gangliosidosis.
What the study was
- Study design
- Cohort study
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Communications medicine
Why it surfaced
Relevant AI/ML in clinical diagnostics and imaging study (promising preliminary signal) meets standard-priority threshold.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.